By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vitro Diagnostics today announced that it has amended an agreement with HemoGenix covering stem cell analysis tools.

The amended agreement expands upon the original agreement to include development of stem cell culture media and high-performance toxicity assays for new cell-based tools for drug discovery and development. The firms also intend to align their respective quality programs to assure consistency, said Golden, Colo.-based Vitro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.